Jenny Zhaoying Xiang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jenny Zhaoying Xiang has a total of 326 co-authors. Here are the top co-authors by number of shared publications:
- Olivier Elemento
Cornell Joan Klein Jacobs Center for Precision Nutrition and Health, Cornell University, Ithaca, USA
23 shared publications - Marcin Imielinski
Cancer Genetics and Genomics Program, Perlmutter Cancer Center, New York University Grossman School of Medicine, New York, USA
22 shared publications - Alexandra E. Kovach
Departments of Laboratory Medicine and Pathology, Boston Children’s Hospital , Boston, MA
21 shared publications - Andriy Derkach
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY
21 shared publications - Bachisio Ziccheddu
Sheila and David Fuente Cancer Biology Graduate Program, University of Miami Miller School of Medicine, Miami, Florida
21 shared publications - Bhavneet Bhinder
Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY 10021, USA
21 shared publications
Latest Publications
- 14 May 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (11) , 2484-2496
Urinary single-cell transcriptomics in kidney transplantation: Elucidation of donor-recipient cellular dynamics and fibrogenic stress
- 14 May 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (11) , 2484-2496
Urinary single-cell transcriptomics in kidney transplantation: Elucidation of donor-recipient cellular dynamics and fibrogenic stress
- Open Access
- 23 April 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (11)
Benchmarking urinary cell transcriptomes for noninvasive differentiation of BK polyomavirus–associated nephropathy from T cell–mediated rejection
BK polyomavirus–associated nephropathy (BKVN) adversely impacts kidney allograft survival and often mimics acute T cell–mediated rejection (TCMR), confounding diagnosis and management. To address this conundrum, we performed unbiased RNA sequencing of urinary cells matched to biopsies classified as BKVN with intragraft inflammation (BKVN-P), BKVN without inflammation (BKVN-N), TCMR, or no rejection (NR). BKVN-N displayed dominant host DNA replication, cell cycle, and repair programs, while BKVN-P samples exhibited expansive innate immune activation, antigen presentation, chemokine upregulation, and epithelial injury. Both BKVN subtypes shared signatures of T cell exhaustion and mature and tolerogenic dendritic cell activation but differed in immune orientation — Th1 predominance in BKVN-N versus Treg and CD8 enrichment in BKVN-P. Compared with TCMR samples, BKVN-P lacked robust TCR/CD28 signaling and was enriched for viral and innate modules; BKVN-N lacked alloimmune activation. B cell exhaustion characterized BKVN-N, while BKVN-P displayed robust B cell activation with metabolic downregulation. A ratiometric urinary cell biomarker, CXCL10 mRNA/CD3E mRNA, distinguished both BKVN subtypes from TCMR with diagnostic accuracy, replicated by quantitative reverse transcription PCR for clinical translation, and confirmed in an independent cohort. These findings demonstrate the utility of urinary cell transcriptomics for resolving viral injury from alloimmunity, enabling precision diagnostics and targeted immunomodulation in kidney transplantation.
- 23 April 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (11)
Open AccessBenchmarking urinary cell transcriptomes for noninvasive differentiation of BK polyomavirus–associated nephropathy from T cell–mediated rejection
BK polyomavirus–associated nephropathy (BKVN) adversely impacts kidney allograft survival and often mimics acute T cell–mediated rejection (TCMR), confounding diagnosis and management. To address this conundrum, we performed unbiased RNA sequencing of urinary cells matched to biopsies classified as BKVN with intragraft inflammation (BKVN-P), BKVN without inflammation (BKVN-N), TCMR, or no rejection (NR). BKVN-N displayed dominant host DNA replication, cell cycle, and repair programs, while BKVN-P samples exhibited expansive innate immune activation, antigen presentation, chemokine upregulation, and epithelial injury. Both BKVN subtypes shared signatures of T cell exhaustion and mature and tolerogenic dendritic cell activation but differed in immune orientation — Th1 predominance in BKVN-N versus Treg and CD8 enrichment in BKVN-P. Compared with TCMR samples, BKVN-P lacked robust TCR/CD28 signaling and was enriched for viral and innate modules; BKVN-N lacked alloimmune activation. B cell exhaustion characterized BKVN-N, while BKVN-P displayed robust B cell activation with metabolic downregulation. A ratiometric urinary cell biomarker, CXCL10 mRNA/CD3E mRNA, distinguished both BKVN subtypes from TCMR with diagnostic accuracy, replicated by quantitative reverse transcription PCR for clinical translation, and confirmed in an independent cohort. These findings demonstrate the utility of urinary cell transcriptomics for resolving viral injury from alloimmunity, enabling precision diagnostics and targeted immunomodulation in kidney transplantation.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1-7 from Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAFV600E Positive Thyroid Carcinoma
S1. BRAFV600E mutation identified in thyroid cancer cell lines analyzed by RNA-seq.S2. STR analysis in thyroid cancer cell lines used in this study.S3. Gene expression of thyroid-specific genes in thyroid cancer cell lines analyzed by RNA-seq.S4. Dose-dependent toxicity of vemurafenib in BRAFV600E thyroidcancer cells.S5. Vemurafenib dose-dependent curves of vemurafenib-resistantBRAFV600E thyroid cancer cells.S6. Vemurafenib induces apoptosis in 8505C cells.S7. Predicted activators and inhibitors in Vem-resistant BRAF mutant thyroid cancer cells.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1-7 from Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAFV600E Positive Thyroid Carcinoma
S1. BRAFV600E mutation identified in thyroid cancer cell lines analyzed by RNA-seq.S2. STR analysis in thyroid cancer cell lines used in this study.S3. Gene expression of thyroid-specific genes in thyroid cancer cell lines analyzed by RNA-seq.S4. Dose-dependent toxicity of vemurafenib in BRAFV600E thyroidcancer cells.S5. Vemurafenib dose-dependent curves of vemurafenib-resistantBRAFV600E thyroid cancer cells.S6. Vemurafenib induces apoptosis in 8505C cells.S7. Predicted activators and inhibitors in Vem-resistant BRAF mutant thyroid cancer cells.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 1-5 from Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAFV600E Positive Thyroid Carcinoma
Supplementary Table 1. Gene expression changes in 8505C after vemurafenib treatment.Supplementary Table 2. Gene expression changes in WRO after vemurafenib treatment.Supplementary Table 3. Gene expression changes in 8505C -Vem-Res 1 relative to parental 8505C.Supplementary Table 4. Gene expression changes in WRO -Vem-Res 6 relative to parental WRO.Supplementary Table 5. Clinical features of thyroid tumors used in Fig. 5.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 1-5 from Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAFV600E Positive Thyroid Carcinoma
Supplementary Table 1. Gene expression changes in 8505C after vemurafenib treatment.Supplementary Table 2. Gene expression changes in WRO after vemurafenib treatment.Supplementary Table 3. Gene expression changes in 8505C -Vem-Res 1 relative to parental 8505C.Supplementary Table 4. Gene expression changes in WRO -Vem-Res 6 relative to parental WRO.Supplementary Table 5. Clinical features of thyroid tumors used in Fig. 5.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from Molecular Evolution of Classic Hodgkin Lymphoma Revealed Through Whole-Genome Sequencing of Hodgkin and Reed Sternberg Cells
R code of our analysis for driver mutation discovery in Hodgkin lymphoma WGS and WES.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from Molecular Evolution of Classic Hodgkin Lymphoma Revealed Through Whole-Genome Sequencing of Hodgkin and Reed Sternberg Cells
R code of our analysis for driver mutation discovery in Hodgkin lymphoma WGS and WES.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data 2 from Molecular Evolution of Classic Hodgkin Lymphoma Revealed Through Whole-Genome Sequencing of Hodgkin and Reed Sternberg Cells
R code of our analysis clock like mutational signatures in Hodgkin lymphoma WGS and WES.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 2 from Molecular Evolution of Classic Hodgkin Lymphoma Revealed Through Whole-Genome Sequencing of Hodgkin and Reed Sternberg Cells
R code of our analysis clock like mutational signatures in Hodgkin lymphoma WGS and WES.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from Molecular Evolution of Classic Hodgkin Lymphoma Revealed Through Whole-Genome Sequencing of Hodgkin and Reed Sternberg Cells
All supplementary figures S1-S17
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from Molecular Evolution of Classic Hodgkin Lymphoma Revealed Through Whole-Genome Sequencing of Hodgkin and Reed Sternberg Cells
All supplementary figures S1-S17
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 2 from Molecular evolution of classic Hodgkin lymphoma revealed through whole genome sequencing of Hodgkin and Reed Sternberg cells
R code of our analysis clock like mutational signatures in Hodgkin lymphoma WGS and WES.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 2 from Molecular evolution of classic Hodgkin lymphoma revealed through whole genome sequencing of Hodgkin and Reed Sternberg cells
R code of our analysis clock like mutational signatures in Hodgkin lymphoma WGS and WES.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from Molecular evolution of classic Hodgkin lymphoma revealed through whole genome sequencing of Hodgkin and Reed Sternberg cells
All supplementary figures S1-S17
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from Molecular evolution of classic Hodgkin lymphoma revealed through whole genome sequencing of Hodgkin and Reed Sternberg cells
All supplementary figures S1-S17